46 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
23 May 24
Regulation FD Disclosure
5:05pm
or grade 4 or higher treatment-related adverse events (TRAEs); the majority of TRAEs were grade 1 or 2, and there were three grade 3 TRAEs (one pyrexia, two
8-K
CADL
Candel Therapeutics Inc
23 May 24
Regulation FD Disclosure
5:05pm
safety and tolerability profile. There were no dose-limiting toxicities or grade 4 or higher treatment-related adverse events (“TRAEs”); the majority
8-K
EX-99.1
dorxo23ggrp359x
6 Dec 22
Regulation FD Disclosure
8:01am
DEF 14A
qo0eu 0onasz
2 Sep 22
Definitive proxy
8:30am
S-3
EX-4.9
1xi9d
5 Aug 22
Shelf registration
5:08pm
S-3
EX-4.8
j13p4r ek1l
5 Aug 22
Shelf registration
5:08pm
S-3
qt1d3aow
5 Aug 22
Shelf registration
5:08pm
8-K
EX-99.1
th5id1 79ew7zh7d
6 Jun 22
Regulation FD Disclosure
8:37am